MY193535A - Cell culture methods - Google Patents

Cell culture methods

Info

Publication number
MY193535A
MY193535A MYPI2019006875A MYPI2019006875A MY193535A MY 193535 A MY193535 A MY 193535A MY PI2019006875 A MYPI2019006875 A MY PI2019006875A MY PI2019006875 A MYPI2019006875 A MY PI2019006875A MY 193535 A MY193535 A MY 193535A
Authority
MY
Malaysia
Prior art keywords
cell culture
culture methods
heterogeneity
proteins
antibodies
Prior art date
Application number
MYPI2019006875A
Other languages
English (en)
Inventor
Andrew Jeffrey Yates
Yahia Bassem Ben
Laetitia Malphettes
Nadine Kochanowski
Gill Renner
Sandrine Durran
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59270991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY193535(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MY193535A publication Critical patent/MY193535A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI2019006875A 2017-05-31 2018-05-29 Cell culture methods MY193535A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1708655.4A GB201708655D0 (en) 2017-05-31 2017-05-31 Cell culture methods
PCT/EP2018/064102 WO2018219968A1 (en) 2017-05-31 2018-05-29 Cell culture methods

Publications (1)

Publication Number Publication Date
MY193535A true MY193535A (en) 2022-10-18

Family

ID=59270991

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019006875A MY193535A (en) 2017-05-31 2018-05-29 Cell culture methods

Country Status (21)

Country Link
US (3) US12077796B2 (enExample)
EP (2) EP4397682A3 (enExample)
JP (3) JP7460370B2 (enExample)
KR (3) KR20240096888A (enExample)
CN (2) CN119326882A (enExample)
AU (2) AU2018276376C1 (enExample)
BR (1) BR112019024390A2 (enExample)
CA (1) CA3065661A1 (enExample)
CL (1) CL2019003459A1 (enExample)
CO (1) CO2019012871A2 (enExample)
EA (1) EA201992828A1 (enExample)
ES (1) ES2978394T3 (enExample)
GB (1) GB201708655D0 (enExample)
HR (1) HRP20240585T1 (enExample)
HU (1) HUE066922T2 (enExample)
IL (2) IL317828A (enExample)
MX (1) MX2019014140A (enExample)
MY (1) MY193535A (enExample)
PL (1) PL3630946T3 (enExample)
RU (2) RU2758674C2 (enExample)
WO (1) WO2018219968A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
CN104152395B (zh) * 2006-11-08 2020-03-10 惠氏公司 合理设计的细胞培养基
US8030027B2 (en) * 2008-04-29 2011-10-04 St. Jude Children's Research Hospital Method for enhancing recombinant antibody production
US8252557B2 (en) 2008-10-28 2012-08-28 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
CA2797140C (en) 2010-04-26 2018-01-23 Novartis Ag Improved cell culture medium
CN102858954A (zh) 2010-04-26 2013-01-02 诺瓦提斯公司 改进的细胞培养方法
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
WO2013158275A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201208367D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
KR102434588B1 (ko) 2014-06-18 2022-08-22 메디뮨 엘엘씨 N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지
KR20170100074A (ko) 2014-12-29 2017-09-04 완롭 위롯페이싯 상승된 전압 및 향상된 장착 방식을 구비한 엔진 연소시스템의 산소효율 증진장치
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
ES2967868T3 (es) 2016-04-28 2024-05-06 Merck Patent Gmbh Método para reducir el nivel de trisulfuro en proteínas
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106222129A (zh) 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods

Also Published As

Publication number Publication date
GB201708655D0 (en) 2017-07-12
AU2024259881A1 (en) 2024-11-28
RU2021128024A (ru) 2021-12-08
CN119326882A (zh) 2025-01-21
US20250066832A1 (en) 2025-02-27
EP3630946C0 (en) 2024-03-27
AU2018276376B2 (en) 2024-08-15
AU2018276376A1 (en) 2019-12-12
AU2024259881B2 (en) 2025-02-13
CN110741077A (zh) 2020-01-31
US20200239923A1 (en) 2020-07-30
JP2022153421A (ja) 2022-10-12
KR20200012972A (ko) 2020-02-05
BR112019024390A2 (pt) 2020-07-14
CO2019012871A2 (es) 2020-01-17
AU2018276376C1 (en) 2025-01-30
CA3065661A1 (en) 2018-12-06
EA201992828A1 (ru) 2020-04-21
IL317828A (en) 2025-02-01
HUE066922T2 (hu) 2024-09-28
IL270880A (en) 2020-01-30
JP2021185185A (ja) 2021-12-09
JP2020521490A (ja) 2020-07-27
WO2018219968A1 (en) 2018-12-06
EP4397682A2 (en) 2024-07-10
MX2019014140A (es) 2020-02-07
KR20250156183A (ko) 2025-10-31
EP3630946A1 (en) 2020-04-08
PL3630946T3 (pl) 2024-07-01
JP7406593B2 (ja) 2023-12-27
US12077796B2 (en) 2024-09-03
RU2019143742A3 (enExample) 2021-06-30
HRP20240585T1 (hr) 2024-07-19
IL270880B1 (en) 2025-01-01
CL2019003459A1 (es) 2020-04-24
ES2978394T3 (es) 2024-09-11
CN110741077B (zh) 2024-10-11
IL270880B2 (en) 2025-05-01
JP7560420B2 (ja) 2024-10-02
EP3630946B1 (en) 2024-03-27
US20250051824A1 (en) 2025-02-13
JP7460370B2 (ja) 2024-04-02
KR20240096888A (ko) 2024-06-26
RU2758674C2 (ru) 2021-11-01
RU2019143742A (ru) 2021-06-30
EP4397682A3 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
PH12019501227A1 (en) Synthetic immune receptors and methods of use thereof
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2021008142A (es) Metodos para cosechar cultivos de celulas de mamifero.
MY208943A (en) Taurine supplemented cell culture medium and methods of use
PH12022550373A1 (en) Ex vivo gamma delta t cell populations
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
MX389823B (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
SG10201809152QA (en) Recombinant host cell for expressing proteins of interest
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2016011465A (es) Drimenol-sintasas y metodos para producir drimenol.
EA202091349A1 (ru) Способы культивирования клеток
MY193535A (en) Cell culture methods
EA201791233A1 (ru) Материал стволовых клеток и способ его получения
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
MX2016013955A (es) Drimenol-sintasas y metodo de produccion de drimenol.
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
MX2020002382A (es) Métodos y composiciones para mejorar la expresión de proteínas recombinantes.
MX2018013683A (es) Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos.
WO2015117033A3 (en) Methods of increasing protein production in mammalian cells